ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

QL2108

A development code. Also written as “QL2108 injection”.

Its studies are mostly in Dermatitis, Atopic, led by Qilu Pharmaceutical.

Furthest: phase 3, since Mar 13, 20252 company-led studies, 1 open or runningNext primary completion: May 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical21 open or runningphase 3since Mar 13, 2025Sep 24, 2024May 2027phase 3 · NCT06884891

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 24, 2024First study: phase 1 study in Dermatitis, AtopicFirst studyNCT06614907 · 198 enrolled · China
  2. Mar 13, 2025Phase 3 study in Dermatitis, AtopicNCT06884891 · 520 planned

Ahead

  1. May 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT06884891

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06884891Dermatitis, Atopic3Not yet recruitingMay 2027520
NCT06614907Dermatitis, Atopic · China1CompletedNov 15, 2024198

How it is read

Names in the registry

  • “QL2108 injection”, 2 entries

Codes read as this program: QL2108.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.